Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/PGP.0b013e31820dc776 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancer.
Sci Rep
January 2025
Department of Life Technologies, Division of Biotechnology, University of Turku, Medisiina D, 5th floor, Kiinamyllynkatu 10, 20520, Turku, Finland.
Glycosylation changes of circulating proteins carrying the CA19-9 antigen may offer new targets for detection methods to be explored for the diagnosis of epithelial ovarian cancer (EOC). Search for assay designs for targets initially captured by a CA19-9 antigen reactive antibody from human body fluids by probing with fluorescent nanoparticles coated with lectins or antibodies to known EOC associated proteins. CA19-9 antigens were immobilized from ascites fluids, ovarian cyst fluids or serum samples using monoclonal antibody C192 followed by probing of carrier proteins using anti-MUC16, anti-MUC1 and, anti STn antibodies and seven lectins, all separately coated on nanoparticles.
View Article and Find Full Text PDFUnveiling a Large Pelvic Mass in a Middle-Aged Woman: The Consequences of Neglected Gynecological Care.
Cureus
December 2024
Obstetrics and Gynecology, Cape Fear Valley Health, Fayetteville, USA.
Pelvic masses in women can originate from both gynecological and non-gynecological sources, necessitating careful evaluation to ensure appropriate treatment. Gynecological masses can range from functional ovarian cysts and tubo-ovarian abscesses to malignant and benign tumors. This case report presents a mucinous borderline ovarian tumor (BOT), a rare type of ovarian neoplasm.
View Article and Find Full Text PDFPediatric Borderline Ovarian Tumors: A Retrospective Study of 15 Cases at a Single Institution.
J Pediatr Hematol Oncol
January 2025
Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX.
Borderline ovarian tumors (BOTs) are rare in pediatric populations and typically follow an indolent clinical course with few reported recurrences. Consequently, guidelines for pediatric BOT management are minimal. We retrospectively examined the management of 15 adolescent patients who underwent BOT resection at our institution over 14 years, with a specific focus on recurrence.
View Article and Find Full Text PDFLocal Recurrence of Premalignant and Early Malignant Rectal Polyps Treated by TEM-A Single-Center Experience.
J Clin Med
December 2024
Department of Surgery, Rabin Medical Center-Hasharon Hospital, Faculty of Medicine, Tel Aviv University, Petach Tikva 49100, Israel.
Transanal endoscopic microsurgery (TEM) is a minimally invasive approach for excising rectal polyps, particularly those with high-grade dysplasia (HGD) or early-stage rectal cancer (T1). This study aimed to evaluate the recurrence risk and its associated factors in patients treated with TEM for HGD and T1 rectal tumors. A retrospective review was conducted on 79 patients who underwent TEM for rectal lesions at Rabin Medical Center-Hasharon Hospital from 2005 to 2019.
View Article and Find Full Text PDFEffects of Fertility-Sparing Surgery on Prognosis and Fertility of Patients With Ovarian Borderline Tumors.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao
December 2024
Department of Obstetrics and Gynecology, Women and Children's Hospital of Ningbo University,Ningbo,Zhejiang 315000,China.
Objective To compare the safety and efficacy of fertility-sparing surgery in patients with ovarian borderline tumors (BOT). Methods A total of 121 BOT patients undergoing fertility-sparing surgery between January 2010 and October 2022 were retrospectively analyzed.The univariate analysis,multivariate analysis,and survival curves were employed to evaluate the clinicopathological and surgical variables and fertility.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!